These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32316346)

  • 21. Clostridium difficile infection: A brief update on emerging therapies.
    Goldberg EJ; Bhalodia S; Jacob S; Patel H; Trinh KV; Varghese B; Yang J; Young SR; Raffa RB
    Am J Health Syst Pharm; 2015 Jun; 72(12):1007-12. PubMed ID: 26025991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and therapy of severe Clostridioides difficile infections in the ICU.
    Guery B; Barbut F; Tschudin-Sutter S
    Curr Opin Crit Care; 2020 Oct; 26(5):450-458. PubMed ID: 32739967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of adult Clostridium difficile digestive contaminations: a literature review.
    Mathias F; Curti C; Montana M; Bornet C; Vanelle P
    Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):209-231. PubMed ID: 30498879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The management of
    Deac IŞ; Ofrim AM; Fărcaş RA; Grad S; Popa ŞL; Dumitraşcu DL
    Med Pharm Rep; 2024 Jan; 97(1):5-11. PubMed ID: 38344334
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.
    Novosad SA; Mu Y; Winston LG; Johnston H; Basiliere E; Olson DM; Farley MM; Revis A; Wilson L; Perlmutter R; Holzbauer SM; Whitten T; Phipps EC; Dumyati GK; Beldavs ZG; Ocampo VLS; Davis CM; Kainer M; Gerding DN; Guh AY
    J Gen Intern Med; 2020 Feb; 35(2):412-419. PubMed ID: 31768906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clostridium difficile infection: a review of current and emerging therapies.
    Ofosu A
    Ann Gastroenterol; 2016; 29(2):147-54. PubMed ID: 27065726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of
    Al-Jashaami LS; DuPont HL
    Gastroenterol Hepatol (N Y); 2016 Oct; 12(10):609-616. PubMed ID: 27917075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of refractory or recurrent Clostridium difficile infection].
    Kim SW
    Korean J Gastroenterol; 2012 Aug; 60(2):71-8. PubMed ID: 22926117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controversies in the Prevention and Treatment of
    Bainum TB; Reveles KR; Hall RG; Cornell K; Alvarez CA
    Microorganisms; 2023 Feb; 11(2):. PubMed ID: 36838352
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for
    Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
    Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
    Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breakthroughs in the treatment and prevention of Clostridium difficile infection.
    Kociolek LK; Gerding DN
    Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):150-60. PubMed ID: 26860266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updates on
    Grace E; Chahine EB
    Sr Care Pharm; 2019 Jan; 34(1):29-42. PubMed ID: 30821676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which is the Preferred Regimen for Non-Severe
    Kim J; Kim J; Kim B; Pai H
    Infect Chemother; 2022 Jun; 54(2):213-219. PubMed ID: 35706079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges and opportunities in the management of Clostridium difficile infection.
    DuPont HL
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clinical and Laboratory Impact of Upgrading Clostridioides (formerly Clostridium) difficile Infection Testing from Routine to Molecular Based-Algorithm: an Observational Case-Study from the Eastern Province, Saudi Arabia.
    Alnimr A; Alwazzeh MJ; Al-Ameer A
    Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Severe and Fulminnant Clostridioides difficile Infection.
    Cheng YW; Fischer M
    Curr Treat Options Gastroenterol; 2019 Dec; 17(4):524-533. PubMed ID: 31745820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of acute and recurrent Clostridium difficile infections : What is new?].
    von Braun A; Lübbert C
    Internist (Berl); 2018 May; 59(5):505-513. PubMed ID: 29536125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.